Xiaomeng K. Xie - Publications

Bimiralisib suppresses proliferation and migration of gastric cancer cells via PI3K/mTOR pathway inhibition.

Journal: The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology

Published: April 23, 2026

From Orange to Oncology: Anti-Inflammatory and Anti-Cancer Mechanisms of Sinensetin.

Journal: Cells

Published: November 26, 2025

Identification of sinensetin as a selective inhibitor for mitogen-activated protein kinase kinase 6 and an anticancer agent for non-small cell lung cancer.

Journal: American journal of cancer research

Published: November 06, 2024

OSGIN1 is a novel TUBB3 regulator that promotes tumor progression and gefitinib resistance in non-small cell lung cancer.

Journal: Cellular and molecular life sciences : CMLS

Published: April 17, 2023

Association between metabolically healthy obesity and incident risk of stroke in adult aged over 40 from rural Henan province

Journal: Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

Published: April 05, 2022

Hippocalcin-like 1 is a key regulator of LDHA activation that promotes the growth of non-small cell lung carcinoma.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: January 17, 2022

Ethyl Ferulate Suppresses Esophageal Squamous Cell Carcinoma Tumor Growth Through Inhibiting the mTOR Signaling Pathway.

Journal: Frontiers in oncology

Published: September 20, 2021

Harmaline isolated from Peganum harmala suppresses growth of esophageal squamous cell carcinoma through targeting mTOR.

Journal: Phytotherapy research : PTR

Published: April 05, 2021

Ipriflavone Suppresses Growth of Esophageal Squamous Cell Carcinoma Through Inhibiting mTOR In Vitro and In Vivo.

Journal: Frontiers in oncology

Published: January 02, 2021

Anwulignan is a novel JAK1 inhibitor that suppresses non-small cell lung cancer growth.

Journal: Journal of cellular and molecular medicine

Published: October 28, 2020

2,6-DMBQ suppresses cell proliferation and migration via inhibiting mTOR/AKT and p38 MAPK signaling pathways in NSCLC cells.

Journal: Journal of pharmacological sciences

Published: September 14, 2020

2,6-DMBQ is a novel mTOR inhibitor that reduces gastric cancer growth in vitro and in vivo.

Journal: Journal of experimental & clinical cancer research : CR

Published: February 22, 2020